COVID-19: A Healthcare Stakeholders Analysis in the United States and EU-5

COVID-19: Monitoring Impacts and Anticipating Trends to Limit Downturn and Optimize Rebound

Publications
Published on:
April 14, 2020

A Healthcare Stakeholders Analysis in the United States and EU-5 and a Practical Guide for Product Suppliers

The COVID-19 pandemic is having a disruptive effect on every corner of the healthcare industry, but its impact on individual stakeholders varies widely. Differences in exposure to COVID-19 patients, the relevance of product portfolios to the disease, and the level of preparedness for a pandemic have forced many across the industry to re-evaluate their strategies, quickly pivot to support urgent needs, and work to strengthen their position for the long-term rebound.

Alira Health’s team of strategists, scientists, doctors, and bankers continue to monitor the key trends and will share their perspective on underlying short, medium and long term implications to support the industry through this crisis and help continue to move healthcare forward during this time of uncertainty.

This 20-page report includes comprehensive analyses of the COVID-19 impact as of April 14, including:

  • An up-to-date digest of the impact COVID-19 is having on key healthcare stakeholders
  • Analysis of key trends and anticipated emerging needs
  • Business approaches for short-term reaction, and business model adaptations to help optimize for the rebound

 

Download our latest report: COVID-19:

Monitoring Impacts and Anticipating Trends to Limit Downturn and Optimize Rebound

Report Download

For more information please contact our team:

Alira Health makes no representations or warranties, either expressed or implied, as to the accuracy of the information in this report. Alira Health has collected and compiled the presented information on a best effort basis under time and budget constraints. In no event will Alira Health be held liable for any direct, indirect, incidental or consequential damages arising out of the use of the information in this report.

Unless otherwise explicitly stated, all information is copyrighted by Alira Health, irrespective of whether a copyright symbol and statement is present. All trademarks are acknowledged.

Related news

Regulatory
Events July 20, 2021
Webinar Recap: Risk Management & Regulatory Submissions
Download Alira Health's Senior Vice President, Regulatory Affairs, Mary McNamara-Cullinane's webinar presentation, How to Implement Risk Management into Regulatory Submissions Using(...)
Regulatory
Publications July 20, 2021
Infographic: The Pre-IND to Market Approval Roadmap in the U.S.
Download our latest infographic, The Pre-IND to Market Approval Roadmap in the U.S.
Regulatory
Multimedia April 29, 2021
Alira Health Webinar Replay: Trends and Challenges in US and EU Combination Product Landscapes
Rewatch this timely webinar with Alira Health’s Regulatory leadership team featuring key insights and advice for U.S. and EU companies as they map out their own regulatory pathways(...)
Regulatory
News February 2, 2021
We Secured Breakthrough Device Designation from FDA on PEDRA Xauron Perfusion System
We are proud to announce the firm’s Regulatory practice has secured a Breakthrough Device Designation from FDA for the real-time tissue perfusion system, PEDRA Xauron Perfusion System.
Clinical Regulatory
News January 7, 2021
Alira Health Adds CMC Services through Acquisition of Chamow & Associates
We have acquired Chamow & Associates (www.chamowassociates.com), a California-based integrated CMC advisory firm. This acquisition brings expertise in biologics manufacturing, quality(...)
Advanced Analytics
News December 1, 2020
We Achieved AWS Select Consulting Partner Status
We have recently earned Amazon Web Services (AWS) Select Consulting Partner status. The firm’s newly formed Advanced Analytics practice will leverage AWS’s cloud computing capabilities(...)
Advanced Analytics Regulatory Research & Development
News November 20, 2020
Alira Health’s Ventures Portfolio Company, X-COR Therapeutics, Closes Initial $2.6M Funding Round
Alira Health congratulates X-COR Therapeutics for closing a $2.6M seed financing to continue developing its novel extracorporeal carbon dioxide removal device toward clinical trials.(...)

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.